Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Market Cap	4.89M 4.3M 3.99M 3.67M 6.88M 473M 7.01M 47.73M 18.62M 231M 18.34M 17.94M 801M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.26M 10.46M 9.62M 18.04M 1.24B 18.36M 125M 48.77M 605M 48.05M 47.01M 2.1B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
27/04/20	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
08/04/20	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
31/03/20	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
30/03/20	Motion for Asset Sale Approved for Aradigm Corporation	CI
09/03/20	Bidding Procedure Approved for Aradigm Corporation	CI
21/02/20	Motion for Asset Sale Filed by Aradigm Corporation	CI
21/02/20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
06/11/19	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
31/10/19	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
22/10/19	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19/07/19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

16/06/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/06/20	ARADIGM CORP : Other Events (form 8-K)	AQ
30/04/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/04/20	ARADIGM CORP : Other Events (form 8-K)	AQ
06/04/20	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Aradigm Corporation Stock

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	+6.73%	-	-	702K
LONZA GROUP AG	+0.57%	-3.87%	-3.64%	+12.42%	46.35B
REVOLUTION MEDICINES, INC.	-0.61%	+0.91%	+404.73%	+624.21%	40.13B
BEONE MEDICINES AG	-0.01%	+5.03%	+10.54%	+67.84%	36.33B
IQVIA HOLDINGS INC.	+0.95%	+1.10%	+3.84%	-8.60%	34.6B
CELLTRION, INC.	+1.23%	-2.05%	+0.56%	+30.76%	26.77B
ASCENDIS PHARMA A/S	+0.93%	-2.31%	-	-	16.66B
MEDPACE HOLDINGS, INC.	-0.45%	+11.86%	+32.00%	+143.58%	16.91B
EUROFINS SCIENTIFIC SE	-0.30%	-6.20%	+0.03%	+7.71%	13.05B
ICON PUBLIC LIMITED COMPANY	-0.93%	-0.68%	-13.42%	-30.41%	13.05B
Average	+0.16%	+1.09%	+54.33%	+105.94%	24.38B
Weighted average by Cap.	+0.29%	+0.23%	+74.69%	+135.33%

	2016	2017
Net sales	195K 172K 159K 147K 275K 18.88M 280K 1.91M 743K 9.21M 732K 716K 31.96M	14.46M 12.72M 11.82M 10.87M 20.38M 1.4B 20.75M 141M 55.12M 683M 54.3M 53.13M 2.37B
Net income	-32.94M -28.97M -26.91M -24.75M -46.42M -3.19B -47.25M -322M -126M -1.56B -124M -121M -5.4B	-10.7M -9.42M -8.75M -8.04M -15.09M -1.04B -15.36M -105M -40.8M -506M -40.19M -39.32M -1.75B
Net Debt	-9.37M -8.24M -7.66M -7.04M -13.21M -908M -13.44M -91.57M -35.72M -443M -35.18M -34.42M -1.54B	7.91M 6.96M 6.47M 5.95M 11.15M 766M 11.35M 77.31M 30.16M 374M 29.71M 29.06M 1.3B